Company news

Pulse Biosciences, Inc news in 2024

Pulse Biosciences, Inc's news releases, calls and decks from 2024, newest first.

View company

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

December 22, 2024

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

December 18, 2024

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

December 16, 2024

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

October 30, 2024

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

October 29, 2024

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

October 29, 2024

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

October 20, 2024

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

August 11, 2024

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

August 11, 2024

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

August 7, 2024

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

July 28, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

July 7, 2024

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

July 2, 2024

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

June 27, 2024

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

June 3, 2024

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

May 19, 2024

Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

May 15, 2024

Pulse Biosciences Enhances Executive Leadership Team

May 13, 2024

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

May 8, 2024

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

May 6, 2024

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

May 1, 2024

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

April 23, 2024

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

March 27, 2024

Pulse Biosciences Announces Plans to Initiate a Rights Offering

March 27, 2024

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

March 13, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

March 7, 2024

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

February 13, 2024

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

January 30, 2024

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

January 1, 2024

Calls in 2024

Decks in 2024